During a presentation by Dr Faisal BinDail, Chairman of the National Committee for Pharmaceutical Industries, titled Delivering Saudi Arabia’s Vision 2030, a range of topics related to the pharmaceutical industry were discussed, including incentives for stimulating local manufacturing and the opportunities the emerging contract manufacturing sector present.
Dr. BinDail said: “In the context of Saudi Arabia, Pharma manufacturing holds an important position in achieving the Kingdom’s Vision 2030. The regulatory body, local industry players, global companies have realised the importance of this initiative and are working towards strengthening of localised Pharmaceutical manufacturing. Part of the transformation plan in the kingdom is to raise the percentage of total pharmaceutical production to 40% from the current 20%. The Government is supportive, local companies are gearing up and the regulatory body is encouraging, facilitating and providing incentives – thereby encouraging global companies to take advantage of this opportunity.
“Moreover, there is an enthusiasm among the local players to raise their standards and provide quality affordable medicines. Saudi Arabia is one of the few countries to adopt track and trace system to curb the menace of counterfeit.”
Saudi Arabia is the largest pharmaceutical market in the MENA region worth US$7.5 billion dollars and is expected to grow at a CAGR of around 5.5%.
“The market is dominated by branded products, as there is a preference for brands locally, but at the same time there is an opportunity for generics as well to expand. Around 20% of the Pharma market is locally manufactured, while 80% is still imported from different countries, from the US, Europe, and different parts of the world, this is in brief how the Pharmaceutical market in Saudi Arabia currently looks like,” added Dr. BinDail.
CPhI Middle East and Africa, which was officially opened by His Excellency Sheikh Nahyan bin Mubarak al Nahyan, Minister of Tolerance, is set to close tomorrow, Wednesday 18th September. Sponsored by the Ministry of Health and Protection (MoHaP), CPhI is attracting attendees from the Middle East and Africa (MEA) - of which the MENA region accounts for 4% of the global pharma market. The event is providing a showcase for over 290 exhibitors and is expected to attract more than 4,900 pharma professionals from around the world.
CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, North America, Korea, China, India, Japan, Southeast Asia and the Middle East, and co-locates with ICSE for contract services, P-MEC for machinery, equipment & technology, FDF for finished dosage formulations, InnoPack for pharmaceutical packaging and BioPh for biopharma. CPhI provides an online buyer & supplier directory at CPhI-Online.com.
For more information visit: www.cphi.com
About Informa Markets
Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com.